Pharma BD Deal Intelligence
Trade-press coverage of the definitive agreement for Jazz to acquire EUSA Pharma for up to $700M, adding Erwinaze and EUSA's U.S./European specialty commercial…
Jefferies' Corey Davis called the Jazz-EUSA deal 'stellar,' said Jazz paid a good price, raised price target to $74 from $64, and pegged Erwinaze US…
EUSA close gives Jazz an established US/EU specialty oncology commercial platform anchored by Erwinaze, the only approved option for ALL patients…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Jazz Pharmaceuticals acquired EUSA Pharma for $650M cash plus up to $50M contingent milestone. Brought Erwinaze (key US ALL salvage therapy) and EUSA's specialty commercial infrastructure. Expected $210-230M revenue contribution in 2013.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Jazz Pharmaceuticals plc / EUSA Pharma (this deal) | 2012 | $700M | 60 |
| Jazz Pharmaceuticals plc / Gentium S.p.A. | 2013 | $1.0B | 51 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
← Browse all deals · How we score deals
More: 2012 deals · Hematology deals